SLNC.F Stock Overview
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.
Silence Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.75|
|52 Week High||US$46.50|
|52 Week Low||US$5.00|
|1 Month Change||3.69%|
|3 Month Change||0.31%|
|1 Year Change||-25.00%|
|3 Year Change||754.43%|
|5 Year Change||525.00%|
|Change since IPO||411.36%|
Recent News & Updates
|SLNC.F||US Biotechs||US Market|
Return vs Industry: SLNC.F underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: SLNC.F underperformed the US Market which returned -11.5% over the past year.
|SLNC.F Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: Insufficient data to determine SLNC.F's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine SLNC.F's volatility change over the past year.
About the Company
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.
Silence Therapeutics Fundamentals Summary
|SLNC.F fundamental statistics|
Is SLNC.F overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLNC.F income statement (TTM)|
|Cost of Revenue||UK£8.19m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-257.95%|
How did SLNC.F perform over the long term?See historical performance and comparison
Is Silence Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SLNC.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SLNC.F's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: SLNC.F is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SLNC.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLNC.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLNC.F is overvalued based on its PB Ratio (121.5x) compared to the US Biotechs industry average (1.5x).
How is Silence Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLNC.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLNC.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLNC.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLNC.F's revenue is expected to decline over the next 3 years (-11.7% per year).
High Growth Revenue: SLNC.F's revenue is forecast to decline over the next 3 years (-11.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLNC.F's Return on Equity is forecast to be high in 3 years time
How has Silence Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLNC.F is currently unprofitable.
Growing Profit Margin: SLNC.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLNC.F is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare SLNC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLNC.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SLNC.F has a negative Return on Equity (-969.27%), as it is currently unprofitable.
How is Silence Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SLNC.F's short term assets (£76.9M) exceed its short term liabilities (£15.7M).
Long Term Liabilities: SLNC.F's short term assets (£76.9M) exceed its long term liabilities (£67.1M).
Debt to Equity History and Analysis
Debt Level: SLNC.F is debt free.
Reducing Debt: SLNC.F has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SLNC.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SLNC.F is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.7% per year.
What is Silence Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLNC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SLNC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLNC.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLNC.F's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SLNC.F has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Craig Tooman (55 yo)
Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer & Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N.V. since June 2019. He...
CEO Compensation Analysis
Compensation vs Market: Craig's total compensation ($USD3.10M) is about average for companies of similar size in the US market ($USD3.83M).
Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.
Experienced Management: SLNC.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: SLNC.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Silence Therapeutics plc's employee growth, exchange listings and data sources
- Name: Silence Therapeutics plc
- Ticker: SLNC.F
- Exchange: OTCPK
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$606.091m
- Shares outstanding: 89.79m
- Website: https://www.silence-therapeutics.com
Number of Employees
- Silence Therapeutics plc
- 72 Hammersmith Road
- Greater London
- W14 8TH
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.